YDUQS PARTICIPAÇÕES

Yduqs reported Q2 EPS of $0.0749 (expectation $0.1644) and revenue of $1.39bn (expectation $1.44bn), after which the stock fell about 5.3% in after-hours trading to $7.31. Despite missing market expectations, the company reported 4% revenue and 7% EBITDA growth on a like-for-like basis, improved receivables collection, higher operating cash flow (BRL 225m H1) and reduced net debt (1.55x EBITDA). Management expects a stronger second half thanks to improved enrollments after the World Cup, confirmed full-year targets for free cash flow and EPS, and plans further expansion at IDOMED and Ibmec. » More on de.investing.com

YDUQS missed analyst expectations in Q1 2026 with EPS of $0.4944 (estimate $0.606) and revenue of $1.51bn (expectation $1.58bn). At the same time the company reported a record free cash flow to equity of BRL 276m (+10%) and a consolidated EBITDA margin above 30%. The stock rose 7.35% in after-hours trading, supported by strong premium brands (Ibmec, Idomed) and the rollout of the AI platform “Play” to boost efficiency. YDUQS confirms an EPS target of $0.36 for 2026 and expects rising revenues for 2027, but sees risks from regulation and macroeconomic pressure. » More on de.investing.com

YDUQS reported revenue of R$1,568 million in Q1 2026 (+5%), which nevertheless missed analyst expectations, and an adjusted net income of R$150 million (earnings per share R$0.57 vs. consensus R$0.606). Free cash flow to equity holders reached R$276 million, a record for a first quarter, and pushed the stock up 6% to R$10.77. Adjusted EBITDA rose 7% to R$552 million with a margin of 35%, and the premium brands Idomed and Ibmec now account for 49% of EBITDA. YDUQS reduced leverage (Net/EBITDA 1.53x), maintained its full-year guidance and expects free cash flow to equity holders of R$520–620 million as well as EPS of R$1.4–2.0 for 2026. » More on de.investing.com